Increasing importance of dry eye syndrome and the ideal artificial tear: Consensus views from a roundtable discussion

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2149-2157

  Asbell, Penny A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Artificial tears; Dry eye syndrome; Ocular surface; Preservative free; Preservatives

Indexed keywords

ARTIFICIAL TEAR;

COST EFFECTIVENESS ANALYSIS; DRY EYE; EYE CARE; EYE PROTECTION; HUMAN; MEDICAL INFORMATION; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DRUG CONTAMINATION; DRUG COSTS; DRY EYE SYNDROMES; HUMANS; OPHTHALMIC SOLUTIONS; PRACTICE GUIDELINES; PRESERVATIVES, PHARMACEUTICAL; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; VISCOSITY;

EID: 33751244206     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132640     Document Type: Review

References (73)

1. Dogru M, Tsubota K. New insights into the diagnosis and treatment of dry eye. Ocul Surface 2004;2:59-75
2. Smith G. Pathology of the tear film. In: The tear film: structure, function and clinical examination, chapter 5. Oxford: Butterworth-Heinemann; 2002
3. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J 1995;21:221-32
4. American Academy of Ophthalmology. Preferred practice pattern®. Dry eye syndrome, 2003. Available from http://www.aao.org/aao/ education/library/ ppp/upload/Dry-Eye-Syndrome_.pdf [accessed 16 August 2006]
5. Department of Health. PRODIGY guidance: dry eye syndrome. Crown Copyright, Department of Health, 2005. Available from http://www.prodigy.nhs.uk/ dry_eye_syndrome [accessed 16 August 2006]
6. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther 2000;17:84-93
7. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 2005;46:46-50
8. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723-8
9. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26
10. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-8
11. The Schepens Eye Research Institute. Dry eye fact sheet, 2005. Available from http://www.theschepens.org/dry_eye_ fact_sheet.htm [accessed 16 August 2006]
12. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol 2001;45(Suppl 2):S199-S202
13. Dogru M, Stern ME, Smith JA, et al. Changing trends in the definition and diagnosis of dry eyes. Am J Ophthalmol 2005;140:507-8
14. Pflugfelder SC, Tseng SCG, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56
15. Asbell P. Artificial tears: past, present, and future. Presented at Proceedings of the 5th International Symposium on Ocular Pharmacology and Therapeutics - ISOPT. Monte Carlo, Monaco. Italy: Medimond, 2004
16. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol 2002;506:989-98
17. Montes-Micó R, Cáliz A, Alió JL. Changes in ocular aberrations after instillation of artificial tears in dry-eye patients. J Cataract Refract Surg 2004;30:1649-52
18. Chiou AG, Florakis GJ, Kazim M. Management of conjunctival cicatrizing diseases and severe ocular surface dysfunction. Surv Ophthalmol 1998;43:19-46
19. Allergan. 2001 Annual Report. Irvine, Calif: Allergan, Inc., 2001.
20. Pflugfelder SC, Solomon A, Dursun D, Li D-Q. Dry eye and delayed tear clearance: 'a call to arms'. Adv Exp Med Biol 2002;506:739-43
21. Göbbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992;99:873-8
22. Sail KN, Cohen SM, Christensen MT. Efficacy and compatibility of an HP-Guar based lubricant eye drop when used as supportive therapy with a cyclosporine-based ophthalmic emulsion. 2020/ B789. Presented at Association for Research in Vision and Ophthalmology annual meeting, Fort Lauderdale, Florida, May 1-5, 2005
23. Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clin Exp Optom 2001;84:4-18
24. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61
25. Toda I, Fujishima H, Tsubota K. Ocular fatigue is the major symptom of dry eye. Acta Ophthalmol (Copenh) 1993;71:347-52
26. Begley CG, Chalmers RL, Mitchell GL, et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001;20:610-8
27. Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003;110:1412-9
28. Huang F-C, Tseng S-H, Shih M-H, Chen FK. Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 2002;109:1934-40
29. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23:762-70
30. Farris RL. The diagnosis and management of the dry eye. J Ophthalmic Nurs Technol 1997;16:164-74
31. Adatia FA, Michaeli-Cohen A, Naor J, et al. Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome. Can J Ophthalmol 2004;39:767-71
32. Korb DR, Herman JP, Greiner JV, et al. Lid wiper epitheliopathy and dry eye symptoms. Eye Contact Lens 2005;31:2-8
33. Goto T, Zheng X, Klyce SD, et al. A new method for tear film stability analysis using videokeratography. Am J Ophthalmol 2003;135:607-12
34. Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 2000;19:477-82
35. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. J Am Med Assoc 2001;286:2114-9
36. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab 2000;85:4874-82
37. Lemp MA. The 1998 Castroviejo lecture. New strategies in the treatment of dry-eye states. Cornea 1999;18:625-32
38. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-9
39. Gipson IK, Argüeso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol 2003;231:1-49
40. Argüeso P, Gipson IK. Epithelial mucins of the ocular surface: structure, biosynthesis and function. Exp Eye Res 2001;73:281-9
41. Farris RL. Tear osmolarity - a new gold standard? Adv Exp Med Biol 1994;350:495-503
42. Gilbard JP, Farris RL. Tear osmolarity and ocular surface disease in keratoconjunctivitis sicca. Arch Ophthalmol 1979;97:1642-6
43. Gilbard JP, Rossi SR, Heyda KG. Tear film and ocular surface changes after closure of the meibomian gland orifices in the rabbit. Ophthalmology 1989;96:1180-6
44. Ren H, Wilson G. The effect of a shear force on the cell shedding rate of the corneal epithelium. Acta Ophthalmol Scand 1997;75:383-7
45. Luo L, Li D-Q, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005;31:186-93
46. Li D-Q, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006;82:588-96
47. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surface 2004;2:124-30
48. Asbell PA, Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocul Surface 2005;3:27-40
49. Rieger G. The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol 1992;76:157-8
50. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002;53:263-80
51. Ridder III WH, Lamotte JO, Ngo L, Fermin J. Short-term effects of artificial tears on visual performance in normal subjects. Optom Vis Sci 2005;82:370-7
52. Durand-Cavagna G, Delort P, Duprat P, et al. Corneal toxicity studies in rabbits and dogs with hydroxyethyl cellulose and benzalkonium chloride. Fundam Appl Toxicol 1989;13:500-8
53. US Food and Drug Administration. Code of federal regulations, title 21, 2004. Available from http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?CFRPart=50 [accessed 16 August 2006]
54. Rieger G. Lipid-containing eye drops: a step closer to natural tears. Ophthalmologica 1990;201:206-12
55. Bachman WG, Wilson G. Essential ions for maintenance of the corneal epithelial surface. Invest Ophthalmol Vis Sci 1985;26:1484-8
56. Lemp MA, Goldberg M, Roddy MR. The effect of tear substitutes on tear film break-up time. Invest Ophthalmol 1975;14:255-8
57. Tiffany JM. The viscosity of human tears. Int Ophthalmol 1991;15:371-6
58. Snibson GR, Greaves JL, Soper NDW, et al. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye 1990;4:594-602
59. Chowdary KPR, Rao YS. Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull 2004;27:1717-24
60. Jones MB, Please CP, McElwain DLS, et al. Dynamics of tear film deposition and draining. Math Med Biol 2005;22:265-88
61. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205-15
62. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol 1992;110:528-32
63. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res 2001;22:8-18
64. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK 1985;104:402-9
65. Lopez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. Curr Eye Res 1991;10:645-56
66. Noecker R. Ophthalmic preservatives: considerations for long-term use in patients with dry eye or glaucoma. Review of Ophthalmology, 2001. Available from http://www.revophth. com/2001/june/cme0601.htm [accessed 16 August 2006]
67. GenTeal® Artificial Tears Product Information. Novartis Ophthalmics Canada, 2005. Available from http://www. novartisophthalmics.ca/e/products/ genteal.shtml [accessed 16 August 2006]
68. Refresh Tears® Product Information. Irvine, Calif: Allergan, Inc., 2005. Available from http://www.allergan.com/site/products/ practitioners/?id= refresh_tears&largeText=no [accessed 16 August 2006]
69. Paugh JR, Brennan NA, Efron N. Ocular response to hydrogen peroxide. Am J Optom Physiol Optics 1988;65:91-8
70. American Optometric Association. Care of the patient with ocular surface disorders. St. Louis (MO): American Optometric Association; 2003. Available from http://www.aoa.org/ documents/CPG-10.pdf [accessed 16 August 2006]
71. Manni G, Centofanti M, Oddone F, et al. Interleukin-1β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol 2005;139:72-7
72. Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42
73. US Government Printing Office. Title 21: food and drugs: 200.50 ophthalmic preparations and dispensers. Electronic Code of Federal Regulations (e-CFR), 1982. Available from http://ecfr.gpoaccess.gov [accessed 16 August 2006]